If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Diffuse large B-cell lymphoma (DLBCL) harbors defects in the proliferation pathway.
We performed multiparameter analysis of proteins expressed during different cell-cycle
phases and correlated them with clinical parameters of head and neck DLBCLs.
Thirty-nine DLBCLs were staged and immunohistochemically stained with MCM2, ki67 and
geminin. Receiver-operating characteristic curve and its area-under-curve (AUC) were
calculated and sensitivity vs specificity curve analysis was performed.
The highest labeling-index was in MCM2 followed by ki67 and geminin (P<0.001). All
pairs showed significant differences (P<0.001). Best cut-off points to differentiate
limited from advanced disease were 68% and 45% for MCM2 and ki67, respectively. There
was no acceptable cut-off for geminin (AUC=0.667, P=0.134). MCM2/ki67 (P=0.293) and
geminin/ki67 (P=0.233) ratios did not differ between the stages. Median(IQR) of geminin/ki67
ratio was 0.57(0.68), translating to a reduced-G1.
We suggest a role for cell-cycle-related proteins in the biology and behavior of DLBCLs.
MCM2 and ki67 cut-offs can be a potential option to differentiate limited from advanced
disease, where imaging and laboratory techniques are unavailable. G1 decrease and
the significantly higher MCM2 expression compared to ki67, indicate replication disturbances,
making factors involved in the G1 phase, targets for treatment.
To read this article in full you will need to make a payment